Urinary Biomarker Analysis of the SANCTUARY Trial
Clinical Journal of the American Society of Nephrology · 22.10.2026
DOI: 10.2215/cjn.0000001243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 22.10.2026. Verfasst von Tobin J Cammett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Biomarker Research, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease.
Abstract (Originalsprache)
Key Points Baseline urinary soluble C5b-9/creatinine, complement factor Ba/creatinine, cluster of differentiation 163/creatinine, and kidney injury molecule-1/creatinine levels were significantly elevated in participants with IgA nephropathy versus healthy donors. Urinary soluble C5b-9/creatinine was elevated in 93% of participants. Ravulizumab significantly reduced urinary biomarkers of complement activation, renal inflammation, and proximal tubular injury versus placebo.
Background
Complement activation in IgA nephropathy drives inflammation, nephron loss, and progressive kidney damage. We evaluated urinary biomarkers among participants with IgA nephropathy treated with ravulizumab (RAV; terminal complement C5 inhibitor) versus placebo (PBO) in the phase 2 Study of Ravulizumab in Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy trial and healthy donors.
Methods
This exploratory analysis evaluated data from 60 participants with IgA nephropathy from Study of Ravulizumab in Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy (NCT04564339) and 25 healthy donors. Spot urine samples were collected predose on days 1, 15, 71, 127, and 183, and thereafter Q8W. Urinary biomarkers of complement activation (soluble C5b-9 [sC5b-9] and complement factor Ba [Ba]), renal inflammation cluster of differentiation 163 (CD163), and tubular injury (kidney injury molecule-1 [KIM-1], neutrophil gelatinase-associated lipocalin) were assessed, normalized to creatinine (Cr). Biomarkers were compared between subgroups: baseline (BL) 24-hour urine protein (1–2 versus >2 g/d) and eGFR (30–60 versus ≥ 60–90 versus ≥ 90 ml/min per 1.73 m 2 ). RAV and PBO groups were compared using mixed model for repeated measures.
Results
BL levels of sC5b-9/Cr, Ba/Cr, CD163/Cr, and KIM-1/Cr were significantly elevated in participants with IgA nephropathy versus healthy donors ( P < 0.001 for all); 93% participants had elevated sC5b-9/Cr. BL sC5b-9/Cr, CD163/Cr, and KIM-1/Cr were significantly higher in participants with BL urine protein >2 g/d versus 1–2 g/d ( P < 0.05 for all). BL sC5b-9/Cr and Ba/Cr were highest in participants with eGFR 30–60 ml/min per 1.73 m 2 ( P < 0.05 across subgroups). Significantly greater reductions in sC5b-9/Cr and Ba/Cr were observed with RAV versus PBO at Weeks 2, 10, 18, and 26 and in CD163/Cr and KIM-1/Cr at weeks 10, 18, and 26 (mixed model for repeated measures; P < 0.05 for all). Reductions in these biomarkers were sustained through week 50 and were observed after crossover from PBO to RAV at week 26.
Conclusions
RAV led to early, sustained, and significant reductions in urinary biomarkers of complement activation and decreases in markers of renal inflammation and proximal tubular injury; this is consistent with its observed effect on proteinuria. Clinical Trial registration number: NCT04564339.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Biomarker Research, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut.
- Biostatistics, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
- Clinical Development, Alexion, AstraZeneca Rare Disease, Dublin, Ireland.
- Clinical Development, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
- Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
ORCID-Profile: Ellen E Millman, Julio Luna, Kara Rice, Youssef M K Farag, Richard Lafayette, Jonathan Barratt
Förderung
- Alexion, AstraZeneca Rare Disease
Zitieren
APA
Cammett, T. J., Millman, E. E., Luna, J., Rice, K., Nolan, S., Farag, Y. M. K., Lafayette, R., & Barratt, J. (2026). Urinary Biomarker Analysis of the SANCTUARY Trial. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001243
Vancouver
Cammett TJ, Millman EE, Luna J, Rice K, Nolan S, Farag YMK, et al. Urinary Biomarker Analysis of the SANCTUARY Trial. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001243
BibTeX
@article{Cammett2026,
author = {Cammett, Tobin J and Millman, Ellen E and Luna, Julio and Rice, Kara and Nolan, Stephen and Farag, Youssef M K and Lafayette, Richard and Barratt, Jonathan},
title = {Urinary Biomarker Analysis of the SANCTUARY Trial},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001243}
}
EUVIMED